U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07331467) titled 'Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE' on Dec. 11, 2025.
Brief Summary: This is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous CD19-targeted CAR-T cells in the treatment of refractory systemic lupus erythematosus.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus
Intervention:
BIOLOGICAL: CD19 CAR-T cells
Three dose groups (1.5x10^5/kg, 5x10^5/kg, 10x10^5/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
Recruitment Status: RECRUITING
Sponsor: Chongqing Preci...